Canbridge can-can

Why Aveo's AV-203 is leading Canbridge to venture outside Asia

Canbridge Life Sciences Ltd.'s deal with Aveo Pharmaceuticals Inc. will see the Chinese biotech developing its first programs outside Asia. But Chairman and CEO James Xue says the company is not deviating from its strategy, which is focused on in-licensing clinical assets from the West to target diseases prevalent in Asia.

In this particular case, it made sense to take rights to Aveo's AV-203 in all territories outside North America because the target indication also plays to Canbridge's experience with Orphan diseases in the West.

AV-203 is an antibody against Erb-b2 receptor tyrosine kinase 3 (ERBB3; HER3; EGFR3) that

Read the full 999 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE